Soluble RAGE as a severity marker in community acquired pneumonia associated sepsis

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Narvaez Rivera, Rodrigo M ^a   Rendon, Adrian ^b   Salinas Carmona, Mario C ^b   Rosas Taraco, Adrian G ^b  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Community acquired pneumonia; Severity markers; Sofa score; Soluble rage; Survival

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; APACHE; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CURB 65 SCORE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; INFLUENZA A (H1N1); MALE; OUTCOME ASSESSMENT; SCORING SYSTEM; SEASONAL INFLUENZA; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; AGED; BACTERIAL PNEUMONIA; BLOOD; COMMUNICABLE DISEASE; HOSPITALIZATION; INFLUENZA VIRUS A; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INFLUENZA A VIRUS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; PNEUMONIA, BACTERIAL; PROGNOSIS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 84855998850     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-15     Document Type: Article

References (39)

1. Mandell LA, et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-72.
2. Epidemiologic Vigilance 2003, DGE/SSA in Mexico 51st week.
3. Perez-Padilla R, et al. Pneumonia and respiratory failure from swine-origin influenza a (H1N1) in Mexico. N Engl J Med 2009, 361(7):680-689. 10.1056/NEJMoa0904252, 19564631.
4. Martinez-Hernandez F, et al. What happened after the initial global spread of pandemic human influenza virus A (H1N1)? a population genetics approach. Virol J 2010, 7:196. 10.1186/1743-422X-7-196, 2936310, 20727188.
5. Pandemic influenza: the new wave. Lancet Infect Dis 2009, 9(10):583. 10.1016/S1473-3099(09)70236-1, 19778756.
6. Dominguez-Cherit G, et al. H1N1 influenza pandemic of 2009 compared with other influenza pandemics: epidemiology, diagnosis, management, pulmonary complications, and outcomes. Curr Infect Dis Rep 2010, 12(3):204-210. 10.1007/s11908-010-0097-0, 21308531.
7. Bautista E, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362(18):1708-1719.
8. Kumar A, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009, 302(17):1872-1879. 10.1001/jama.2009.1496, 19822627.
9. Webb SA, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009, 361(20):1925-1934.
10. Rello J, et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009, 13(5):R148. 10.1186/cc8044, 2784367, 19747383.
11. Tang CM, Macfarlane JT. Early management of younger adults dying of community acquired pneumonia. Respir Med 1993, 87(4):289-294. 10.1016/0954-6111(93)90025-U, 9728229.
12. Neill AM, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996, 51(10):1010-1016. 10.1136/thx.51.10.1010, 472650, 8977602.
13. Fine MJ, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336(4):243-250. 10.1056/NEJM199701233360402, 8995086.
14. Lee RW, Lindstrom ST. A teaching hospital's experience applying the pneumonia severity index and antibiotic guidelines in the management of community-acquired pneumonia. Respirology 2007, 12(5):754-758. 10.1111/j.1440-1843.2007.01121.x, 17875067.
15. Lim WS, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58(5):377-382. 10.1136/thorax.58.5.377, 1746657, 12728155.
16. Ho KM. Combining sequential organ failure assessment (SOFA) score with acute physiology and chronic health evaluation (APACHE) II score to predict hospital mortality of critically ill patients. Anaesth Intensive Care 2007, 35(4):515-521.
17. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: a review. QJM 2009, 102(6):379-388. 10.1093/qjmed/hcp027, 19299247.
18. Wang H, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285(5425):248-251. 10.1126/science.285.5425.248, 10398600.
19. Angus DC, et al. Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis. Crit Care Med 2007, 35(4):1061-1067. 10.1097/01.CCM.0000259534.68873.2A, 17334246.
20. Sunden-Cullberg J, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005, 33(3):564-573. 10.1097/01.CCM.0000155991.88802.4D, 15753748.
21. Bierhaus A, Stern DM, Nawroth PP. RAGE in inflammation: a new therapeutic target?. Curr Opin Investig Drugs 2006, 7(11):985-991.
22. Liliensiek B, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004, 113(11):1641-1650. 419481, 15173891.
23. Hudson BI, et al. Identification, classification, and expression of RAGE gene splice variants. FASEB J 2008, 22(5):1572-1580.
24. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992, 101(6):1481-1483. 10.1378/chest.101.6.1481, 1600757.
25. Angus DC, Pereira CA, Silva E. Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 2006, 6(2):207-212.
26. Marshall JC, et al. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003, 31(5):1560-1567. 10.1097/01.CCM.0000065186.67848.3A, 12771633.
27. Roch A, et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005, 33(5):1001-1007. 10.1097/01.CCM.0000162561.82012.E9, 15891328.
28. Gibot S, et al. Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005, 33(4):792-796. 10.1097/01.CCM.0000159089.16462.4A, 15818107.
29. Ewig S, Welte T. Biomarkers in the diagnosis of pneumonia in the critically ill: don't shoot the piano player. Intensive Care Med 2008, 34(6):981-984. 10.1007/s00134-008-1088-6, 18392806.
30. Challen K, et al. Evaluation of triage methods used to select patients with suspected pandemic influenza for hospital admission. Emerg Med J 2011, doi:10.1136/emj.2010.104380.
31. Brandao-Neto RA, et al. The role of Pneumonia scores in the emergency room in patients infected by 2009 H1N1 infection. Eur J Emerg Med 2011, doi: 10.1097/MEJ.0b013e328349ed85.
32. Bohrer H, et al. Role of NFkappaB in the mortality of sepsis. J Clin Invest 1997, 100(5):972-985. 10.1172/JCI119648, 508272, 9276714.
33. Gaini S, et al. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 2007, 11(2):R32. 10.1186/cc5715, 2206448, 17346334.
34. Lee N, et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 2007, 45(6):723-731. 10.1086/520981, 17712756.
35. de Jong MD, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12(10):1203-1207. 10.1038/nm1477, 16964257.
36. Alleva LM, Budd AC, Clark IA. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 2008, 181(2):1454-1459.
37. Bopp C, et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res 2008, 147(1):79-83. 10.1016/j.jss.2007.07.014, 17981300.
38. van Zoelen MA, Achouiti A, van der Poll T. RAGE during infectious diseases. Front Biosci (Schol Ed) 2011, 3:1119-1132.
39. Yamagishi S, et al. Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 2006, 55(9):1227-1231. 10.1016/j.metabol.2006.05.007, 16919543.